{"product_id":"natera-business-model-canvas","title":"Natera Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNatera's Business Model: A Strategic Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about how Natera leverages its innovative diagnostics to capture a significant market share? Our Business Model Canvas breaks down their core customer segments, value propositions, and key revenue streams, offering a clear view of their strategic advantage.\u003c\/p\u003e\n\u003cp\u003eDiscover the intricate web of Natera's key partnerships and resources, essential for delivering their cutting-edge solutions. This canvas illuminates their operational efficiency and cost structure, vital for understanding their profitability.\u003c\/p\u003e\n\u003cp\u003eUncover Natera's approach to customer relationships and channels, crucial for their patient and healthcare provider engagement. This deep dive provides actionable insights into their market penetration strategies.\u003c\/p\u003e\n\u003cp\u003eReady to gain a comprehensive understanding of Natera's winning formula? Download the full Business Model Canvas today to unlock a detailed, actionable blueprint for strategic analysis and inspiration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers \u0026amp; Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatera’s foundational partnerships are with healthcare providers and hospital systems, as clinicians are the primary gatekeepers for test orders. Establishing deep relationships with major networks, including large OB\/GYN practices and transplant centers, is crucial for integrating Natera’s diagnostic products into standard care pathways. These collaborations drive significant test volume; for instance, Natera reported over 2.2 million tests processed in 2023, with continued growth projected for 2024, largely fueled by these direct provider relationships. Such partnerships ensure a consistent flow of samples and direct access to their core patient base, supporting their projected 2024 revenue between $1.09 billion and $1.11 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Payors \u0026amp; Government Health Plans\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecuring favorable reimbursement from major private insurers, including UnitedHealth and Aetna, and government health plans like Medicare, is vital for Natera's commercial success. These partnerships ensure Natera's high-value tests, such as Signatera and Prospera, are financially accessible to a broad patient population. Natera reported over 220 million covered lives for Signatera as of early 2024, demonstrating progress in payor engagements. The focus remains on demonstrating clinical utility and cost-effectiveness to achieve comprehensive positive coverage decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera forms crucial partnerships with biopharmaceutical companies, integrating its Signatera test into clinical trials for novel cancer therapies. These collaborations leverage Natera's advanced technology for precise patient selection, monitoring treatment response, and serving as companion diagnostics. By early 2024, Natera reported over 100 active biopharma partnerships, with Signatera being evaluated in more than 100 clinical trials. This strategic alignment generates a significant B2B revenue stream, positioning Natera's technology as a cornerstone in the future development of oncology treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic \u0026amp; Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with leading academic and medical research centers are crucial for validating Natera's advanced technology and discovering new clinical applications. These partnerships, like the recent 2024 studies presented at medical conferences, generate peer-reviewed publications that significantly build credibility and support broader market adoption for tests such as Prospera and Signatera. Such alliances also provide Natera access to cutting-edge research and insights from key opinion leaders in fields like oncology and organ transplant. For instance, Natera often funds research grants, allocating a portion of its R\u0026amp;D budget, which was over $300 million in 2023, towards these university-led initiatives.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eNatera's research collaborations led to over 100 peer-reviewed publications in 2023-2024, enhancing scientific validation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAccess to over 50 key opinion leaders through academic networks informs Natera's product development pipeline in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships facilitate clinical trial enrollment, with Natera often collaborating on trials involving thousands of patients annually.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese relationships are vital for identifying new biomarker discoveries, potentially expanding Natera's test portfolio by 10-15% over the next two years.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributors \u0026amp; Laboratory Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNatera strategically collaborates with international distributors and laboratory partners to broaden its global reach. These essential partners manage complex local regulatory landscapes and logistics, while also providing critical sales and marketing support in their respective regions. This approach enables Natera to achieve capital-efficient market entry and scalable growth beyond the United States, leveraging established networks. For instance, Natera's 2024 expansion efforts continue to rely on such partnerships, evidenced by their ongoing focus on markets like Europe and Asia.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eNatera's global revenue, while primarily US-driven, saw international contributions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic alliances reduce direct operational costs overseas.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships facilitate access to diverse patient populations.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRegulatory navigation by local partners accelerates market penetration.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships Drive Millions of Tests and Billions in Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera's core strategy relies on key partnerships with healthcare providers, notably driving over 2.2 million tests in 2023, and securing payor coverage for 220 million lives by early 2024. Collaborations with over 100 biopharma companies integrate Signatera into clinical trials, contributing to their projected 2024 revenue of $1.09-$1.11 billion. Academic alliances, evidenced by over 100 publications in 2023-2024, validate technology, while international distributors expand global reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003e2024 Impact\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Providers\u003c\/td\u003e\n\u003ctd\u003eDrives test volume\u003c\/td\u003e\n\u003ctd\u003e2.2M+ tests (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayors\u003c\/td\u003e\n\u003ctd\u003eEnsures accessibility\u003c\/td\u003e\n\u003ctd\u003e220M+ covered lives (early 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003eB2B revenue, R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e100+ active collaborations (early 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eNatera's Business Model Canvas outlines its strategy to provide advanced genetic testing services, targeting healthcare providers and patients. It details key resources like proprietary technology and scientific expertise, and revenue streams from diagnostic tests and data services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eNatera's Business Model Canvas acts as a pain point reliever by providing a clear, one-page snapshot of their complex genetic testing services, making it easier to understand their value proposition and operational flow.\u003c\/p\u003e\n\u003cp\u003eIt serves as a powerful tool for Natera to streamline communication and strategy alignment, transforming abstract business concepts into a tangible and actionable framework for all stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch \u0026amp; Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatera's competitive edge stems from continuous innovation in cell-free DNA analysis, bioinformatics, and assay development. Research and Development efforts are intensely focused on enhancing the accuracy of established tests like Panorama and Signatera. These activities also drive the creation of new diagnostic solutions for various diseases. For example, Natera's R\u0026amp;D expenses were approximately $150.3 million for the first quarter of 2024, demonstrating a significant commitment. This substantial investment aims to expand the company's addressable market and solidify its technological leadership in genetic testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Complexity Lab Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatera's core operational activity centers on high-complexity lab operations, processing patient samples in their CLIA-certified and CAP-accredited laboratories. This involves meticulous DNA extraction, advanced sequencing, and comprehensive analysis, ensuring stringent quality control measures are upheld. The company prioritizes efficiency and accuracy, critical for delivering reliable results swiftly; for instance, Natera reported processing over 510,000 total tests in the first quarter of 2024 alone. Maintaining rapid turnaround times is paramount for clinicians and patients relying on timely diagnostic insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSecuring Market Access \u0026amp; Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera dedicates substantial effort to engaging payors, aiming to secure and broaden insurance coverage for its advanced diagnostic tests. This involves meticulously generating and presenting extensive clinical and economic evidence to demonstrate the value and efficacy of tests like Signatera. As of 2024, Natera continues to expand Signatera's commercial coverage, which directly impacts revenue growth and patient access. Success in these negotiations, such as recent expansions for Signatera in colorectal cancer, is vital for Natera's profitability and market penetration. These ongoing efforts ensure more patients can access Natera's innovative technology, driving financial performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales \u0026amp; Clinician Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNatera's specialized sales force actively educates physicians, genetic counselors, and hospital administrators on the clinical benefits of their tests. This involves direct sales calls, participation in medical conferences, and digital marketing to drive adoption. Building strong relationships and trust within the medical community is essential for sustained growth, contributing to their expanding test volumes. For instance, Natera reported robust growth in 2023, with total test volumes reaching 2.4 million, underscoring the effectiveness of their outreach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSpecialized sales force focuses on clinician education.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDirect sales calls and medical conferences are key engagement methods.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDigital marketing supports broader awareness and adoption.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRelationship building drives test volume growth, as seen with 2.4 million tests in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics \u0026amp; Data Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNatera's core strength lies in its sophisticated bioinformatics and data analysis, employing proprietary algorithms and machine learning to interpret complex genetic data. Their advanced pipeline transforms raw DNA sequence information into clinically actionable insights, crucial for tests like Panorama and Prospera. This computational expertise, a key intellectual property, drives Natera's value proposition in the precision medicine market, supporting over 3.5 million tests reported through 2024. The continuous refinement of these algorithms ensures high accuracy and clinical utility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eProprietary algorithms and machine learning are applied to interpret complex genetic data.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNatera's bioinformatics pipeline converts raw DNA sequence information into clinically actionable insights.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis computational expertise forms a critical component of the company's intellectual property.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIt enhances Natera's value proposition in precision medicine, underpinning tests like Panorama and Prospera.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Diagnostics: Innovation, Precision, and Market Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNatera's core activities include extensive Research and Development, like the $150.3 million invested in Q1 2024, to innovate cell-free DNA diagnostics. High-complexity lab operations process over 510,000 tests quarterly, ensuring accurate results. The company actively engages payors to expand insurance coverage and employs a specialized sales force to educate clinicians, driving test adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eKey Metric\/Example\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eInnovation in diagnostics\u003c\/td\u003e\n\u003ctd\u003e$150.3M R\u0026amp;D in Q1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab Operations\u003c\/td\u003e\n\u003ctd\u003eHigh-complexity sample processing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;510,000 tests in Q1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayor \u0026amp; Sales Engagement\u003c\/td\u003e\n\u003ctd\u003eMarket access \u0026amp; adoption\u003c\/td\u003e\n\u003ctd\u003eSignatera coverage expansion 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Natera Business Model Canvas preview you're viewing is the genuine article, not a mockup or sample. This is a direct snapshot from the actual, comprehensive document you will receive upon purchase. You'll gain full access to this professionally structured and formatted Business Model Canvas, ready for immediate use and customization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55480443175289,"sku":"natera-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/natera-business-model-canvas.png?v=1752753808","url":"https:\/\/growthsharematrix.com\/products\/natera-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}